Table 4 Univariate and multivariate Cox proportional hazards analysis in LS-SCLC with high ALI (n = 38).
Variables | Mortality in LS-SCLC with high ALI | |||
|---|---|---|---|---|
Univariable (N = 38) | Multivariable (N = 38) | |||
HR (95% CI) | P-values | HR (95% CI) | P-values | |
Male sex (vs. female) | 1.557 (0.36, 6.65) | 0.5500 | 5.842 (0.93, 36.79) | 0.0601 |
Age, years | 1.016 (0.95, 1.08) | 0.6290 | ||
BMI, kg/m2 | 0.964 (0.84, 1.1) | 0.5904 | ||
Smoking, ever-smoker (vs. never-smoker) | N/A | |||
Radiotherapy dose (Gy), ≥ 60 (vs. 45 ≤ < 60) | 0.742 (0.32, 1.70) | 0.4797 | ||
ECOG PS ≥ 1 (vs. 0) | 1.140 (0.5, 2.59) | 0.7542 | ||
COPD (vs. none) | 0.799 (0.35, 1.85) | 0.5991 | ||
Diabetes (vs. none) | 1.079 (0.44, 2.63) | 0.8670 | ||
Hypertension (vs. none) | 1.365 (0.6, 3.1) | 0.4577 | ||
Chronic kidney disease (vs. none) | 1.715 (0.58, 5.06) | 0.3288 | 3.811 (0.97, 15.01) | 0.0557 |
TNM stage (vs. stage I/II) | ||||
Stage IIIA | 1.293 (0.42, 3.96) | 0.6530 | 2.615 (0.72, 9.49) | 0.1438 |
Stage IIIB/IIIC | 2.401 (0.81, 7.08) | 0.1122 | 5.512 (1.62, 18.78) | 0.0064 |
Schedule of radiotherapy | ||||
Sequential (vs. concurrent) | 0.907 (0.27, 3.06) | 0.8752 | ||
Regimen (vs. etoposide + cisplatin) | ||||
Etoposide + carboplatin | 2.151 (0.78, 5.94) | 0.1393 | 3.211 (1.00, 10.32) | 0.0501 |
Others | N/A | |||
Prophylactic cranial irradiation (vs. none) | 0.681 (0.3, 1.56) | 0.3622 | ||
Consolidation chemotherapy (vs. none) | 0.857 (0.38, 1.96) | 0.7154 | ||
High LDH (vs. low) | 0.926 (0.4, 2.15) | 0.8581 | ||
